ALLUVI: A DETAILED INVESTIGATION INTO RETATRUTIDE'S POTENTIAL

Alluvi, formerly BI 4744, represents a notable development in obesity care. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling efficacy in patient assessments, potentially surpassing available GLP-1 receptor